Neutrophil extracellular traps in cancer <p>Nature Reviews Cancer, Published online: 12 November 2025; <a href="https://www.nature.com/articles/s41568-025-00888-7">doi:10.1038/s41568-025-00888-7</a></p>Neutrophil extracellular traps (NETs) influence cancer initiation, progression and metastasis through immunosuppressive mechanisms within the tumour microenvironment. In this Review, Shahzad et al. highlight our recent understanding of NET biology in cancer and emphasize both the translational data available and the need for further clinical trials evaluating NETs and NET-directed therapies. Nature Reviews Cancer November 12, 2025 Original source
The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma <p>Leukemia, Published online: 12 November 2025; <a href="https://www.nature.com/articles/s41375-025-02809-x">doi:10.1038/s41375-025-02809-x</a></p>The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma Leukemia Journal November 12, 2025 Original source
Correspondence to “Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis” <p>Leukemia, Published online: 12 November 2025; <a href="https://www.nature.com/articles/s41375-025-02812-2">doi:10.1038/s41375-025-02812-2</a></p>Correspondence to “Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis” Leukemia Journal November 12, 2025 Original source
Fat or Muscle on Carboplatin Toxicity in NSCLC? . <br /> Nutrition and Cancer Journal November 11, 2025 Original source
A Teacher’s Troll Helps Her Through Triple-Negative Breast Cancer <p>By Jennifer Peters  On April 23, 2024, my life jumped onto a conveyor belt I never saw coming — one that would race me through numerous exam rooms, tests, and heartfelt conversations. The diagnosis? Triple-negative breast cancer. I’d never even heard of it. I thought breast cancer was all the same. Boy, was I wrong.  But even in that first shocking moment, I knew one thing: I wasn’t going to do ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/11/a-teachers-troll-helps-her-through-triple-negative-breast-cancer/" title="A… Dana-Farber Cancer Institute November 11, 2025 Original source
Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients <p>Prostate Cancer and Prostatic Diseases, Published online: 09 November 2025; <a href="https://www.nature.com/articles/s41391-025-01024-0">doi:10.1038/s41391-025-01024-0</a></p>Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients Prostate Cancer Journal November 11, 2025 Original source
<i>Cyclin D1</i> rearranged diffuse large B-cell lymphoma—an evolving concept <p>Leukemia, Published online: 07 November 2025; <a href="https://www.nature.com/articles/s41375-025-02794-1">doi:10.1038/s41375-025-02794-1</a></p><i>Cyclin D1</i> rearranged diffuse large B-cell lymphoma—an evolving concept Leukemia Journal November 11, 2025 Original source
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial <p>Leukemia, Published online: 07 November 2025; <a href="https://www.nature.com/articles/s41375-025-02795-0">doi:10.1038/s41375-025-02795-0</a></p>The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial Leukemia Journal November 11, 2025 Original source
The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival <p>Leukemia, Published online: 10 November 2025; <a href="https://www.nature.com/articles/s41375-025-02799-w">doi:10.1038/s41375-025-02799-w</a></p>The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival Leukemia Journal November 11, 2025 Original source
TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms <p>Leukemia, Published online: 10 November 2025; <a href="https://www.nature.com/articles/s41375-025-02798-x">doi:10.1038/s41375-025-02798-x</a></p>TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms Leukemia Journal November 11, 2025 Original source
Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study <p>Leukemia, Published online: 10 November 2025; <a href="https://www.nature.com/articles/s41375-025-02807-z">doi:10.1038/s41375-025-02807-z</a></p>Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study Leukemia Journal November 11, 2025 Original source
Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma <p>Leukemia, Published online: 10 November 2025; <a href="https://www.nature.com/articles/s41375-025-02811-3">doi:10.1038/s41375-025-02811-3</a></p>Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma Leukemia Journal November 11, 2025 Original source
Creating a Journey with the Unknown: A Dana-Farber Physician-Scientist Story <p>What makes us humans lies in our genes. But even with all their power, they are remarkably vulnerable to errors.   But these potentially harmful errors are an opportunity for humankind to study and treat, as it has been for Dana-Farber’s physician-scientist Srinivas Viswanathan, MD, PhD. “We have the ability to make an impact,” Viswanathan said. “There are so many unanswered questions in cancer biology still, especially in our understanding of rarer subtypes of kidney cancer.”  … Dana-Farber Cancer Institute November 10, 2025 Original source
Evaluation of the Relationship Between Sarcopenia, Nutritional Status, and Frailty in Older Patients with Cancer . <br /> Nutrition and Cancer Journal November 8, 2025 Original source
Association Between Fat Mass Index, Fat Free Mass Index and Metabolic Syndrome, Cachexia, and All-Cause Mortality Among Patients with Cancer . <br /> Nutrition and Cancer Journal November 7, 2025 Original source
<a href="https://www.fiercebiotech.com/biotech/novo-nordisk-ceo-feels-danish-pharma-will-bag-metsera-end-pfizer-bidding-war" hreflang="en">Novo Nordisk CEO 'feels' Danish pharma will bag Metsera at end of Pfizer bidding war</a> Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma “feels this deal will be closed. FierceBiotech November 7, 2025 Original source
<a href="https://www.fiercebiotech.com/biotech/amgen-halts-gastric-cancer-trial-after-antibody-did-not-meet-our-standard-efficacy" hreflang="en">Amgen halts gastric cancer trial after antibody 'did not meet our standard' of efficacy, exec says</a> Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has stopped another trial of the molecule. FierceBiotech November 7, 2025 Original source
<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25" hreflang="en">Fierce Biotech Fundraising Tracker '25: Braveheart brings in $185M; Azalea opens with $82M</a> The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. FierceBiotech November 7, 2025 Original source
<a href="https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact" hreflang="en">Lilly inks $345M antibody development pact with XtalPi subsidiary</a> Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery shop as much as $345 million. FierceBiotech November 7, 2025 Original source
<a href="https://www.fiercebiotech.com/biotech/lilly-pulls-out-cns-portion-950m-rirpk1-inhibitor-collab-rigel" hreflang="en">Lilly pulls out of CNS portion of $960M RIPK1 inhibitor collab with Rigel</a> Eli Lilly has pulled out of the central-nervous-system-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 inhibitors. FierceBiotech November 7, 2025 Original source